Study to Evaluate Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects

Health Volunteers Clinical Trial

Official title:
A Phase 1, Open-Label, Fixed-Sequence, Drug-Drug Interaction Study to Evaluate the Effect of Multiple Doses of Fluconazole, a CYP3A4 and CYP2C9 Inhibitor, on the Pharmacokinetics of CTP-543 in Healthy Subjects

Status Completed

Clinical Trial Summary

A single center, Phase 1, open-label, fixed-sequence, drug-drug interaction study to evaluate the effect of multiple doses of Fluconazole, a CYP3A4 and CYP2C9 inhibitor, on the pharmacokinetics (PK) of CTP-543 in healthy subjects

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Health Volunteers

Clinical Trial Details

NCT number	NCT05478772
Study type	Interventional
Source	Concert Pharmaceuticals
Contact
Status	Completed
Phase	Phase 1
Start date	July 11, 2022
Completion date	August 12, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01765855` - An Open-Label, Single-Dose, Mass-Balance Study to Assess the Disposition of 14C-Labeled PRT054021 in Healthy Male Subjects	Phase 1
Completed	`NCT02990325` - A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults	Phase 1/Phase 2
Completed	`NCT05467709` - Study To Evaluate The Effect Of Multiple Doses of CTP-543 On The Pharmacokinetics Of Single Doses of Midazolam In Healthy Subjects	Phase 1
Completed	`NCT05467696` - Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers	Phase 1